Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 randomized placebo-controlled multiple ascending dose study of TP-6076 in healthy volunteers
NL-OMON45496Phase 1Active, not recruiting
- Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of TP-6076 in bacterial disease (8 arms), sponsored by Tetraphase Pharmaceuticals, Inc. Primary endpoint: Safety and tolerability. Started Mar 2017; status: active, not recruiting.
02
Drugs
TP-6076
03
Conditions
bacterial disease
Beyond the preview
Go deeper on NL-OMON45496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45496.